<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="In-Process" Owner="NLM">
      <PMID Version="1">35418279</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2222-1751</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>11</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Emerging microbes &amp; infections</Title>
          <ISOAbbreviation>Emerg Microbes Infect</ISOAbbreviation>
        </Journal>
        <ArticleTitle>N-chlorotaurine is highly active against respiratory viruses including SARS-CoV-2 (COVID-19) <i>in vitro</i>.</ArticleTitle>
        <Pagination>
          <StartPage>1293</StartPage>
          <EndPage>1307</EndPage>
          <MedlinePgn>1293-1307</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/22221751.2022.2065932</ELocationID>
        <Abstract>
          <AbstractText><i>N</i>-chlorotaurine (NCT) a long-lived oxidant generated by leukocytes, can be synthesized chemically and applied topically as an anti-infective to different body sites, including the lung via inhalation. Here, we demonstrate the activity of NCT against viruses causing acute respiratory tract infections, namely severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza viruses, and respiratory syncytial virus (RSV). Virucidal activity of NCT was tested in plaque assays, confirmed by RT-qPCR assays. Attack on virus proteins was investigated by mass spectrometry. NCT revealed broad virucidal activity against all viruses tested at 37°C and pH 7. A significant reduction in infectious particles of SARS-CoV-2 isolates from early 2020 by 1 log<sub>10</sub> was detected after 15 min of incubation in 1% NCT. Proteinaceous material simulating body fluids enhanced this activity by transchlorination mechanisms (1 -2 log<sub>10</sub> reduction within 1-10 min). Tested SARS-CoV-2 variants B.1.1.7 (Alpha) und B.1.351 (Beta) showed a similar susceptibility. Influenza virus infectious particles were reduced by 3 log<sub>10</sub> (H3N2) to 5 log<sub>10</sub> (H1N1pdm), RSV by 4 log<sub>10</sub> within a few min. Mass spectrometry of NCT-treated SARS-CoV-2 spike protein and 3C-like protease, influenza virus haemagglutinin and neuraminidase, and RSV fusion glycoprotein disclosed multiple sites of chlorination and oxidation as the molecular mechanism of action. Application of 1.0% NCT as a prophylactic and therapeutic strategy against acute viral respiratory tract infections deserves comprehensive clinical investigation.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lackner</LastName>
            <ForeName>Michaela</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0001-9073-2886</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rössler</LastName>
            <ForeName>Annika</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0002-5298-0288</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Volland</LastName>
            <ForeName>André</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0003-2805-8215</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Stadtmüller</LastName>
            <ForeName>Marlena Nastassja</ForeName>
            <Initials>MN</Initials>
            <Identifier Source="ORCID">0000-0001-8893-5326</Identifier>
            <AffiliationInfo>
              <Affiliation>Unit 17-Influenza and Other Respiratory Viruses, Robert Koch-Institute, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Müllauer</LastName>
            <ForeName>Brigitte</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Banki</LastName>
            <ForeName>Zoltan</ForeName>
            <Initials>Z</Initials>
            <Identifier Source="ORCID">0000-0002-3826-5800</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ströhle</LastName>
            <ForeName>Johannes</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Luttick</LastName>
            <ForeName>Angela</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>360biolabs Pty Ltd, Melbourne, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fenner</LastName>
            <ForeName>Jennifer</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>360biolabs Pty Ltd, Melbourne, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sarg</LastName>
            <ForeName>Bettina</ForeName>
            <Initials>B</Initials>
            <Identifier Source="ORCID">0000-0002-4785-8739</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Medical Biochemistry, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kremser</LastName>
            <ForeName>Leopold</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Innovative Biomedical Concepts, Inc., Staten Island, NY, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tone</LastName>
            <ForeName>Paul</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Innovative Biomedical Concepts, Inc., Staten Island, NY, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Stoiber</LastName>
            <ForeName>Heribert</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0002-4266-8397</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>von Laer</LastName>
            <ForeName>Dorothee</ForeName>
            <Initials>D</Initials>
            <Identifier Source="ORCID">0000-0001-5825-7237</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wolff</LastName>
            <ForeName>Thorsten</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0001-7688-236X</Identifier>
            <AffiliationInfo>
              <Affiliation>Unit 17-Influenza and Other Respiratory Viruses, Robert Koch-Institute, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schwarz</LastName>
            <ForeName>Carsten</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0002-1461-4439</Identifier>
            <AffiliationInfo>
              <Affiliation>CF Center Westbrandenburg, Division Cystic Fibrosis, Pediatric Clinic Westbrandenburg, Potsdam, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nagl</LastName>
            <ForeName>Markus</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-1225-9349</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Emerg Microbes Infect</MedlineTA>
        <NlmUniqueID>101594885</NlmUniqueID>
        <ISSNLinking>2222-1751</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">COVID-19</Keyword>
        <Keyword MajorTopicYN="N">N-chlorotaurine</Keyword>
        <Keyword MajorTopicYN="N">anti-infective</Keyword>
        <Keyword MajorTopicYN="N">antiseptic</Keyword>
        <Keyword MajorTopicYN="N">antiviral</Keyword>
        <Keyword MajorTopicYN="N">influenza</Keyword>
        <Keyword MajorTopicYN="N">respiratory syncytial virus</Keyword>
        <Keyword MajorTopicYN="N">respiratory tract</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>14</Day>
          <Hour>5</Hour>
          <Minute>17</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35418279</ArticleId>
        <ArticleId IdType="doi">10.1080/22221751.2022.2065932</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
